Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients.
A549 Cells
Actin Cytoskeleton
/ drug effects
Active Transport, Cell Nucleus
/ drug effects
Animals
Antiviral Agents
/ pharmacology
Atorvastatin
/ pharmacology
Cell Line, Tumor
Chlorocebus aethiops
Drug Repositioning
HeLa Cells
Humans
Ivermectin
/ pharmacology
NF-kappa B
/ metabolism
SARS-CoV-2
/ drug effects
Vero Cells
alpha Karyopherins
/ metabolism
rho GTP-Binding Proteins
/ metabolism
COVID-19 Drug Treatment
COVID-19
SARS-CoV-2
antihelmintic drug
atorvastatin
drug repurposing
host cell antiviral response
ivermectin
lipophilic statin
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
15 10 2021
15 10 2021
Historique:
received:
30
08
2021
revised:
01
10
2021
accepted:
11
10
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
11
11
2021
Statut:
epublish
Résumé
Nuclear transport and vesicle trafficking are key cellular functions involved in the pathogenesis of RNA viruses. Among other pleiotropic effects on virus-infected host cells, ivermectin (IVM) inhibits nuclear transport mechanisms mediated by importins and atorvastatin (ATV) affects actin cytoskeleton-dependent trafficking controlled by Rho GTPases signaling. In this work, we first analyzed the response to infection in nasopharyngeal swabs from SARS-CoV-2-positive and -negative patients by assessing the gene expression of the respective host cell drug targets importins and Rho GTPases. COVID-19 patients showed alterations in KPNA3, KPNA5, KPNA7, KPNB1, RHOA, and CDC42 expression compared with non-COVID-19 patients. An in vitro model of infection with Poly(I:C), a synthetic analog of viral double-stranded RNA, triggered NF-κB activation, an effect that was halted by IVM and ATV treatment. Importin and Rho GTPases gene expression was also impaired by these drugs. Furthermore, through confocal microscopy, we analyzed the effects of IVM and ATV on nuclear to cytoplasmic importin α distribution, alone or in combination. Results showed a significant inhibition of importin α nuclear accumulation under IVM and ATV treatments. These findings confirm transcriptional alterations in importins and Rho GTPases upon SARS-CoV-2 infection and point to IVM and ATV as valid drugs to impair nuclear localization of importin α when used at clinically-relevant concentrations.
Identifiants
pubmed: 34696514
pii: v13102084
doi: 10.3390/v13102084
pmc: PMC8537229
pii:
doi:
Substances chimiques
Antiviral Agents
0
NF-kappa B
0
alpha Karyopherins
0
Ivermectin
70288-86-7
Atorvastatin
A0JWA85V8F
rho GTP-Binding Proteins
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Universidad Nacional de Quilmes
ID : 1297/19
Organisme : Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Argentina
ID : IP-COVID-19-625
Organisme : Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Argentina
ID : PICT RAICES 2018-02639
Organisme : Agencia Nacional de Promoción de la Investigación, el Desarrollo Tecnológico y la Innovación, Argentina
ID : PICT 2019-03215
Références
J Cell Biol. 2004 Jun 7;165(5):617-23
pubmed: 15184398
J Pharm Sci. 2021 Jun;110(6):2501-2507
pubmed: 33493479
Open Forum Infect Dis. 2021 Aug 09;8(8):ofab394
pubmed: 34410284
EMBO Mol Med. 2021 Aug 9;13(8):e14122
pubmed: 34170074
J Biomol Struct Dyn. 2021 Apr 10;:1-9
pubmed: 33843474
Int J Clin Pract. 2021 Sep;75(9):e14434
pubmed: 34080261
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Am J Physiol Regul Integr Comp Physiol. 2004 Oct;287(4):R759-66
pubmed: 15205185
Clin Exp Metastasis. 2016 Aug;33(6):589-600
pubmed: 27146156
Front Immunol. 2021 Jan 28;11:621441
pubmed: 33584719
STAR Protoc. 2021 Jun 18;2(2):100478
pubmed: 33907739
J Clin Pharmacol. 2002 Oct;42(10):1122-33
pubmed: 12362927
Int J Antimicrob Agents. 2020 Jun;55(6):105969
pubmed: 32278811
Int J Infect Dis. 2021 Aug;109:91
pubmed: 34175482
Genome Biol. 2014;15(12):550
pubmed: 25516281
Inflamm Res. 2008 Nov;57(11):524-9
pubmed: 19109745
EClinicalMedicine. 2021 Jun 18;37:100959
pubmed: 34189446
Antiviral Res. 2013 Sep;99(3):301-6
pubmed: 23769930
Biochem Biophys Res Commun. 2016 Oct 21;479(3):429-433
pubmed: 27622322
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Sci Rep. 2018 Jan 10;8(1):358
pubmed: 29321677
Biochem J. 2012 May 1;443(3):851-6
pubmed: 22417684
PLoS One. 2016 Aug 09;11(8):e0160875
pubmed: 27504984
Sci Rep. 2020 Apr 24;10(1):6935
pubmed: 32332842
Front Pharmacol. 2021 Mar 10;12:625678
pubmed: 33776767
Physiol Rep. 2015 Apr;3(4):
pubmed: 25847914
mBio. 2020 Mar 20;11(2):
pubmed: 32198163
Virology. 2001 May 10;283(2):188-96
pubmed: 11336544
Int J Mol Sci. 2013 Mar 28;14(4):7089-108
pubmed: 23538840
Antiviral Res. 2020 Jun;178:104787
pubmed: 32251768
PLoS Biol. 2020 Sep 8;18(9):e3000849
pubmed: 32898168
JAMA. 2021 Apr 13;325(14):1426-1435
pubmed: 33662102
Blood Coagul Fibrinolysis. 2008 Oct;19(7):709-18
pubmed: 18832915
Int J Antimicrob Agents. 2020 Sep;56(3):106125
pubmed: 32739476
Inflamm Res. 2011 Jun;60(6):589-96
pubmed: 21279416
iScience. 2020 Oct 23;23(10):101585
pubmed: 32989429
Cancer Res. 2005 Aug 15;65(16):7059-64
pubmed: 16103052
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
Cells. 2020 Sep 15;9(9):
pubmed: 32942671
Mol Med Rep. 2009 Jan-Feb;2(1):97-102
pubmed: 21475797
Mucosal Immunol. 2013 May;6(3):474-84
pubmed: 22990623
Int J Oncol. 2015;46(6):2335-45
pubmed: 25846632
Clin Exp Metastasis. 2002;19(6):551-9
pubmed: 12405293